Case 47Semiconductor Roadmap And Capital ExecutionTurnaround

AMD compute-roadmap and funding turnaround

Advanced Micro Devices, Inc. · 2015–2025

For a simulated long-only public-equity committee using only evidence public by May 2, 2016, should it initiate or add AMD exposure, maintain an existing holding without new gates, defer and re-underwrite, or route a possible reduction to an authorized human, and what six evidence gates must govern any later capital action?

Start with Part A Read outcome & teaching note

At the decision boundary

AMD compute-roadmap and funding-resilience re-underwriting decision

Decision time: May 3, 2016
Knowledge cutoff: May 2, 2016
Recommended path: Initiate or add no capital. Roadmap, sampling, licensing, and asset-sale evidence justify continued research, but missing independent product proof, realized segment economics, complete manufacturing and funding schedules, and valuation inputs require abstention. Route any existing holding to authorized human re-underwriting; do not size or execute a trade.
Confidence: Moderate

What happened

No actual investor action is observed. Frozen Part A recorded a simulated defer-and-re-underwrite recommendation with no agent-sized or executed trade. AMD later reported launching Zen-based Ryzen and EPYC products, customer-authored Microsoft and Google adoption signals appeared, and AMD expanded its perimeter through Xilinx, Pensando, and ZT Systems. The selected record does not show that AMD or a real investment committee used Part A's six gates.

Part A's outcome-blind process remains disciplined even though the later selected business endpoints were favorable. At the May 2016 cutoff it separated technical validation, roadmap execution, segment economics, manufacturing and capital, funding resilience, and valuation readiness; it also abstained from price attractiveness, sizing, and execution. Later launches, customer announcements, operating scale, cash generation, and customer availability are evidence updates that could clear some gates prospectively, but mixed product segments, acquisitions, export restrictions, commitments, dilution, and missing valuation inputs show why the gates should not be collapsed. Favorable hindsight does not retroactively make missing cutoff evidence available.

Case inventory

What is inside

14source records

18financial tables

26material claims

3candidate rules

Transfer with care

Rule hypotheses from this case

All rule hypotheses →

Candidatemoderate confidence

rule.stage-semiconductor-roadmaps-behind-independent-and-customer-proof

Defer any agent-proposed exposure increase and route the case to authorized human underwriting; release capital only through precommitted technical, customer-production, stable-scope economic, manufacturing-funding, and valuation gates, with customer announcements treated as one signal rather than complete proof.

A launch can establish availability and a customer announcement can establish a configuration or intended use, but neither alone proves repeat production demand, contribution economics, manufacturing resilience, or an attractive security price.

Candidatehigh confidence

rule.bridge-acquisition-and-reporting-perimeters-before-causal-attribution

Require a deterministic pre-close, acquired, retained, discontinued, and consolidated bridge before causal or organic-growth language; preserve original and recast presentation vintages, and abstain from sole attribution when stable-scope product economics remain unavailable.

Acquisitions, divestitures, discontinued operations, segment aggregation, and issued shares can change both the numerator and denominator, so a mathematically correct endpoint comparison can still be non-organic and causally ambiguous.

Candidatemoderate confidence

rule.separate-regulatory-charges-and-conditional-dilution-gates

Track gross charge, reversal, and net period effect as separate issuer-attributed records; track issued, vested, exercisable, exercised, outstanding, and maximum conditional shares separately; run downside funding and per-share stress tests under authorized human review without treating reversals as certainty or conditional maxima as realized dilution.

Regulatory decisions can impair inventory and market access before recoveries are known, while milestone warrants can create economic exposure without being vested or outstanding; premature netting hides path dependence and overstates certainty.

Read against

A contrasting case sharpens the boundary.

Semiconductor Roadmap And Capital ExecutionIntel compute-roadmap and capital-economics failureFor a simulated long-only public-equity committee using only evidence public by May 2, 2016, should any new Intel exposure be initiated or added, and what technical, roadmap, segment, manufacturing, funding, and valuation gates should govern human re-underwriting of any existing holding?